tiprankstipranks
Trending News
More News >

NetraMark to Unveil Cutting-Edge AI Clinical Trial Tools at ISCTM Meeting

Story Highlights
  • NetraMark specializes in AI tools that enhance predictive modeling in clinical trials.
  • NetraMark’s new AI tools significantly improve treatment predictions in CNS trials.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
NetraMark to Unveil Cutting-Edge AI Clinical Trial Tools at ISCTM Meeting

Confident Investing Starts Here:

NetraMark Holdings ( (TSE:AIAI) ) just unveiled an announcement.

NetraMark Holdings Inc. announced that it will present new data on its AI-based clinical trial treatment separation tools at the ISCTM Annual Meeting. The tools are designed to improve predictive modeling and patient stratification in CNS clinical trials, offering significant advancements in identifying effective treatments for disorders like major depressive disorder and schizophrenia. These innovative methods have shown improved accuracy and specificity over traditional models, potentially transforming the design and analysis of such trials.

More about NetraMark Holdings

NetraMark Holdings Inc. is a leader in generative AI software focused on clinical trial analytics. The company specializes in developing machine learning tools that enhance predictive modeling and patient stratification, particularly in psychiatric clinical trials.

YTD Price Performance: 7.43%

Average Trading Volume: 8,232

Technical Sentiment Consensus Rating: Sell

See more insights into AIAI stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App